HC Wainwright Equities Analysts Decrease Earnings Estimates for Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Analysts at HC Wainwright cut their FY2028 earnings per share estimates for shares of Fulcrum Therapeutics in a research note issued on Tuesday, May 14th. HC Wainwright analyst A. Fein now anticipates that the company will earn $0.51 per share for the year, down from their previous estimate of $0.54. HC Wainwright currently has a "Buy" rating and a $17.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($1.76) per share.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last announced its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.04. Fulcrum Therapeutics had a negative return on equity of 38.94% and a negative net margin of 3,470.05%. The firm had revenue of $0.87 million during the quarter, compared to analyst estimates of $0.65 million.

Several other analysts also recently weighed in on FULC. Royal Bank of Canada assumed coverage on Fulcrum Therapeutics in a research note on Wednesday, March 13th. They issued an "outperform" rating and a $14.00 price target on the stock. The Goldman Sachs Group upgraded Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $6.00 to $15.00 in a research note on Monday. Piper Sandler lifted their price objective on Fulcrum Therapeutics from $13.00 to $15.00 and gave the company an "overweight" rating in a research note on Wednesday, February 28th. Finally, Oppenheimer lowered their price objective on Fulcrum Therapeutics from $16.00 to $14.00 and set an "outperform" rating for the company in a research note on Tuesday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Fulcrum Therapeutics currently has an average rating of "Buy" and a consensus price target of $14.33.

Fulcrum Therapeutics Stock Up 4.3 %

Shares of NASDAQ:FULC traded up $0.34 during trading on Wednesday, hitting $8.25. The stock had a trading volume of 1,029,202 shares, compared to its average volume of 626,776. Fulcrum Therapeutics has a 12 month low of $2.65 and a 12 month high of $13.70. The company has a market capitalization of $512.74 million, a PE ratio of -5.30 and a beta of 2.35. The firm's fifty day moving average is $8.68 and its 200 day moving average is $7.32.

Insiders Place Their Bets

In other Fulcrum Therapeutics news, VP Greg Tourangeau sold 4,884 shares of Fulcrum Therapeutics stock in a transaction on Friday, March 8th. The stock was sold at an average price of $11.72, for a total value of $57,240.48. Following the completion of the sale, the vice president now owns 11,807 shares of the company's stock, valued at approximately $138,378.04. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company's stock.

Institutional Trading of Fulcrum Therapeutics

Several large investors have recently modified their holdings of the company. StemPoint Capital LP grew its holdings in shares of Fulcrum Therapeutics by 8.1% in the first quarter. StemPoint Capital LP now owns 407,108 shares of the company's stock worth $3,843,000 after acquiring an additional 30,535 shares during the period. Vanguard Group Inc. grew its holdings in shares of Fulcrum Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company's stock worth $23,965,000 after acquiring an additional 18,681 shares during the period. SG Americas Securities LLC bought a new stake in shares of Fulcrum Therapeutics in the first quarter worth $115,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Fulcrum Therapeutics in the first quarter worth $308,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Fulcrum Therapeutics by 66.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company's stock worth $112,000 after acquiring an additional 4,766 shares during the period. Institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.